Atlas Trials

NAUTILUS: OKI-179 Plus Binimetinib in Patients with Advanced Solid Tumors in the RAS Pathway (Phase 1b) and NRAS-mutated Melanoma (Phase 2)

Clinical trial NCT05340621 · COMPLETED

Trial details

NCT number
NCT05340621
Sponsor
OnKure, Inc.
Status
COMPLETED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
RAS MutationNRAS Gene MutationMelanoma
Start date
2022-05-11
Primary completion
2025-01-29
Enrollment
36

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.